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A B S T R A C T
PAR4 is expressed by a variety of cells, including platelets, cardiac, lung and immune cells. We investigated the
contribution of PAR4 to viral infections of the heart and lung. Toll-like receptor (TLR) 3-dependent immune
responses were analyzed after co-stimulation of PAR4 in murine bone-marrow derived macrophages, embryonic
fibroblasts and embryonic cardiomyocytes. In addition, we analyzed Coxsackievirus B3 (CVB3) or H1N1 influ-
enza A virus (H1N1 IAV) infection of PAR4−/− (ΔPAR4) and wild-type (WT) mice. Lastly, we investigated the
effect of platelet inhibition on H1N1 IAV infection. In vitro experiments revealed that PAR4 stimulation enhances
the expression of TLR3-dependent CXCL10 expression and decreases TLR3-dependent NFκB-mediated proin-
flammatory gene expression. Furthermore, CVB3-infected ΔPAR4 mice exhibited a decreased anti-viral response
and increased viral genomes in the heart leading to more pronounced CVB3 myocarditis compared to WT mice.
Similarly, H1N1 IAV-infected ΔPAR4 mice had increased immune cell numbers and inflammatory mediators in
the lung, and increased mortality compared with infected WT controls. The study showed that PAR4 protects
mice from viral infections of the heart and lung.
1. Introduction
Protease-activated receptors (PARs) are a family of 4 G-protein
coupled receptors (PAR1-4) [1,2]. Serine proteases and matrix me-
talloproteinases (MMPs), including immune cell-derived proteases and
coagulation proteases, can either activate or inactivate PARs depending
on the cell type and post-translational modification of the PAR [3]. For
instance, thrombin activates both PAR1 and PAR4 as well as human
PAR3. Human platelets express PAR1 and PAR4, whereas PAR4 is the
functional thrombin receptor on mouse platelets since they lack PAR1
[4,5]. A PAR1 inhibitor is FDA-approved to reduce platelet activation in
patients in combination with standard anti-platelet dual therapy [6].
However, chronic PAR1 inhibition can increase the risk of hemorrhagic
strokes potentially due to a protective role of PAR1 on vascular in-
tegrity [6].
We and others showed that PARs are modulators of antiviral re-
sponses to infections with the RNA viruses Coxsackievirus B3 (CVB3)
and H1N1 influenza A virus (H1N1 IAV) [3,7–10]. For instance, we and
others reported that PAR1 enhances and PAR2 inhibits toll-like receptor
(TLR3) dependent anti-viral immune responses [7–9,11,12].
Furthermore, we found that thrombin inhibition reduced immune re-
sponses to a TLR3 agonist in mice and increased CVB3 myocarditis
[8,11]. In line with our findings, a recent study showed that thrombin
inhibition reduced TLR3-dependent responses in human bronchial
epithelial cells [12].
Importantly, there are some conflicting data regarding the con-
tribution of PARs to the outcome in viral infection of the lung [1]. We
observed that PAR1-deficiency increased H1N1 infection of mice [8],
whereas another group showed a protection in PAR1−/− mice after IAV
infection [10]. In addition, we and others found that PAR2−/− mice
were protected from H1N1 infection [9,13]. However, another group
found that PAR2−/− mice exhibited more severe disease after H1N1
IAV infection [14]. The reasons for these opposing data are unclear and
are the object of ongoing investigations.
Recent studies have focused on PAR4 as a druggable target to re-
duce platelet activation and thrombosis [15,16]. Like PAR1, many cells
other than platelets express PAR4, including cardiac myocytes (CMs)
and immune cells [3,17]. Interestingly, two studies have suggested that
PAR4 antagonism might promote cardiac protection by inhibiting car-
diomyocyte apoptosis and pathologic platelet activation in ischemia
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reperfusion injury [15,17]. Furthermore, a recent study showed that 
repeated administration of a PAR4 inhibitor (pepducin P4pal-10) in 
wild-type (WT) mice daily between day 2 and 4 after infection resulted 
in reduced H1N1 IAV infection-mediated lung inflammation and im-
proved survival [18].
In the study here, we used global PAR4 deficient mice, to investigate 




Adult PAR4−/− (ΔPAR4) and WT (PAR4+/+) mice on the C57Bl/6 
background were used for this study [5]. All animal experiments were 
performed in accordance with the guidelines of the animal care and use 
committee of the UNC at Chapel Hill and complies with National In-
stitutes of Health guidelines.
2.2. In vitro experiments
Bone marrow-derived macrophages (BMM) were generated from 
WT and ΔPAR4 mouse bone marrow using the L929-conditioned media 
method [11]. Mouse embryonic fibroblasts (MEFs) and murine CMs 
were isolated from WT mouse embryos (E14) as described [7,8]. Male 
and female mice were used to ensure equally sex distribution within the 
cell preparations. BMMs, MEFs and CMs were cultured in DMEM 
(Gibco, Gaithersburg, MD, USA) supplemented with 10% FBS and 1%
penicillin/streptomycin [7,11]. Cells were stimulated under FBS-free 
conditions with 25 μg/mL of the TLR3 agonist poly-
inosinic:polycytidylic acid (poly I:C, γ-radiated; Sigma-Aldrich, St. 
Louis, Mo, USA) and/or PAR4 agonist peptide (AP, AYPGKF, 150 μM, 
Abgent, San Diego, Calif., USA) or thrombin (Thr, 5 nM, human α-
thrombin; Enzyme Research Laboratories, South Bend, IN, USA).
For splenocyte isolation, WT and ΔPAR4 spleens were harvested and 
passed through a 70-μm cell strainer to generate a single-cell suspen-
sion. RBCs were lysed and the splenocytes washed and resuspended at a 
density of 2 × 106 cells per well of a 24-well plate in RPMI 1640 with 
10% FBS and 1% penicillin/streptomycin. Cells were stimulated over-
night with PAR4 AP (150 μM). The next day, splenocytes were used in a 
natural killer (NK) cell cytotoxicity assay against YAC-1 target cells as 
described in detail elsewhere [19].
For CVB3 in vitro infectivity studies, CMs were incubated with CVB3 
(Nancy Strain, multiplicity of infection = 1) for 45 min, washed and 
stimulated with thrombin (5 nM) or PAR4 AP (150 µM) for 6 h under 
FBS-free conditions [7].
2.3. Real-time PCR and ELISA
Cardiac injury was quantified by measuring plasma cardiac tro-
ponin-I using an ELISA [8,20]. Viral genomes and TNFα mRNA ex-
pression were analyzed by real-time PCR [11]. Expression data were 
normalized to hypoxanthine-guanine phosphoribosyltransferase 
(HPRT). Interferon β (IFNβ) and CXCL10, CXCL1, CCL5, MCP1 and 
TNFα protein levels were analyzed by ELISA as described [8,11]. Levels 
of IgG2a were measured with a mouse IgG2a ELISA kit from (Abcam, 
Cambridge, UK).
2.4. Virus infection models
For the CVB3 myocarditis model, male mice aged 6–8 weeks were 
infected interperitoneally with 105 plaque-forming units of CVB3 
(Nancy Strain) in 200 µL PBS [8]. Virus was propagated and titered as 
described [7]. Heart function was measured on conscious mice by 
echocardiography using a VisualSonics Vevo 2100 ultrasound system as 
described [8,20].
For the H1N1 IAV infection model, the mouse‐adapted strain of 
influenza A/Puerto Rico/8/1934 (PR/8) was propagated in 10–12 day 
of embryonated eggs and titered with a hemagglutination unit (HAU) 
assay [21,22]. WT and ΔPAR4 mice of both sexes between 8 and 
12 weeks were infected intranasally with 0.02 HAU in 50 µL PBS as 
described [8,21,22]. To analyze immune cell infiltration and cytokine/
chemokine levels, bronchiolar alveolar lavage fluid (BALF) was col-
lected and processed from infected and uninfected mice by postmortem 
lavage with 3 × 900 µL ice-cold PBS as described [21,22]. Immune cell 
and red blood cell (RBC) numbers were determined with a Hemavet 
950 (Drew Scientific, Miami Lakes, FL, USA) [21,22]. Mice were eu-
thanized if they had ≥25% loss of initial body weight, as specified in 
our animal protocol [21,22].
2.5. Histology
Lung tissues from WT and ΔPAR4 mice were fixed in 4% formalin 
and paraffin-embedded, cut to 4 µm thick sections and stained with H& 
E [22].
2.6. Platelet inhibition
To inhibit platelet activation, acetylsalicylic acid (ASA, 0.4 mg/mL, 
Sigma-Aldrich) or clopidogrel (0.15 mg/mL, Bristol-Myers Squibb/
Sanofi Pharmaceuticals Partnership Bridgewater, NJ, USA) was given 
via drinking water (ad lib) 3 days prior and after H1N1 IAV infection 
[23,24]. Arachidonic acid-induced (2.5 mM) or ADP-induced (10 µM) 
platelet activation, measured as integrin αIIbβ3 activation, was in-
hibited in platelets isolated from ASA- or clopidogrel-treated mice, re-
spectively.
2.7. Statistics
GraphPad Prism 8.01 (GraphPad Software Inc., La Jolla, CA) was 
used for statistical analysis. Data are represented as mean ± SEM. The 
2-tailed Student’s t test was used for 2-group comparison of normally 
distributed data. Mann-Whitney test was used for 2-group comparison 
of not normally distributed data. For multiple-group comparison, nor-
mally distributed data were analyzed by 1- or 2-way ANOVA tests and 
were Bonferroni-corrected for repeated measures over time. Survival 
rates were analyzed by Kaplan-Meier analysis and the log-rank test was 
applied to compare the survival distribution between the two groups. P-
value ≤ 0.05 was regarded as significant.
3. Results
3.1. PAR4 activation increases CXCL10 expression in BMMs and MEFs
In previous studies, we showed that TLR3-depdendent CXCL10 ex-
pression in response to the dsRNA mimetic poly I:C was enhanced by 
co-stimulation of PAR1 on macrophages and cardiac fibroblasts [8,11]. 
Here, we investigated if PAR4 activation also enhances poly I:C induced 
CXCL10 expression in BMMs and MEFs. First, we analyzed poly I:C 
induction of CXCL10 protein expression in BMMs derived from WT and 
ΔPAR4 mice. Poly I:C but not the PAR4 activating protease thrombin 
induced CXCL10 protein expression in both WT and ΔPAR4 BMMs 
(Fig. 1A). Importantly, co-stimulation with poly I:C and thrombin sig-
nificantly increased CXCL10 protein expression in WT BMMs (Fig. 1A). 
As expected from our previous study [11], thrombin increased CXCL10 
protein expression in poly I:C treated ΔPAR4 BMMs since these cells 
express PAR1. However, the CXCL10 expression in ΔPAR4 BMMs was 
significant lower compared to co-stimulated WT BMMs (Fig. 1A). In 
addition, ΔPAR4 BMMs exhibited significant lower CXCL10 levels 
compared to WT BMMs when stimulated with poly I:C alone, suggesting 
that the cells may produce a PAR4 activating protease similarly to our 
recent study with PAR1 [8,11]. To further test if specific PAR4
stimulation increases poly I:C-induced CXCL10 expression in WT
BMMs, we used a PAR4 AP. PAR4 AP alone had no effect on CXCL10
expression of WT BMMs (Fig. 1B). Poly I:C increased CXCL10 expres-
sion and additional co-stimulation with the PAR4 AP further increased
this expression (Fig. 1B). Similar responses of the CXCL10 expression
were observed with WT MEFs (Fig. 1C) where poly I:C induced the
CXCL10 expression and co-stimulation with PAR4 AP further enhanced
the expression of CXCL10 (Fig. 1C).
3.2. PAR4 activation reduces expression of pro-inflammatory mediators
after poly I:C stimulation of MEFs and CMs
Recently, we reported that PAR1 activation reduces the TLR3-de-
pendent expression of TNFα [1]. To analyze if PAR4 activation pro-
duces similar modulation of TLR3 signaling, we analyzed the expression
of the proinflammatory chemokine MCP1 and the cytokine TNFα in
MEFs and murine CMs after stimulation with PAR4 AP and/or poly I:C.
PAR4 AP alone did not induce MCP1 or TNFα protein expression in WT
MEFs (Fig. 1D and E) or TNFα mRNA expression in WT CMs (Fig. 1F).
Poly I:C alone led to significantly increased induction of MCP1 and
TNFα protein expression in WT MEFs (Fig. 1D and E) and TNFα mRNA
expression in WT CMs (Fig. 1F). Interestingly, co-stimulation with poly
I:C and PAR4 AP reduced poly I:C induction of both MCP1 and TNFα
protein expression in WT MEF and TNFα mRNA expression in WT CMs
(Fig. 1D-F).
3.3. PAR4 activation has no effect on early CVB3 replication in CMs
CMs, which express PAR4, are the primary site of CVB3 replication
in the heart [25]. To analyze if PAR4 activation directly influences
CVB3 replication in CMs, WT CMs were infected with CVB3 and sti-
mulated with either thrombin or PAR4 AP. Thrombin but not PAR4 AP
stimulation of murine CMs after CVB3 reduced the levels of CVB3
genomes (Fig. 1G) suggesting that PAR1 but not PAR4 reduces CVB3
Fig. 1. PAR4 activation modulates innate immune responses in vitro. (A) Levels of CXCL10 in cell culture media of bone marrow-derived macrophages from WT
(white bars) and PAR4−/− (ΔPAR4, black bars) mice in response to the dsRNA mimetic poly I:C (25 µg/mL) and/or thrombin (Thr, 5 nM) were analyzed after 7 h
stimulation. WT BMM (B) or WT murine embryonic fibroblasts (C) were stimulated with poly I:C (25 µg/mL) and/or PAR4 activating peptide (AP, 150 µM) for 7 h
and the CXCL10 protein levels analyzed in cell culture media by ELISA. WT MEF (D, E) were stimulated for 24 h with poly I:C (25 µg/mL) and/or PAR4 AP (150 µM)
and the MCP1 and TNFα protein levels were analyzed in the cell culture media by ELISA. (F) TNFα mRNA expression was analyzed by real-time PCR in WT murine
CM 4 h after stimulation with poly I:C (25 µg/mL) and/or PAR4 AP (150 µM). Results are shown relative to poly I:C stimulation which was set to 1. (G) CVB3 genomes
were analyzed in WT murine CM by RT-PCR after infection with CVB3 (multiplicity of infection 1) and additional stimulation with thrombin (Thr, 5 nM) or PAR4 AP
(150 µM) for 6 h. Genome levels were normalized to HPRT mRNA expression. (H) Natural killer (NK) cell cytotoxicity against YAC-1 cells of splenocytes isolated from
WT (white bars) and ΔPAR4 (black bars) mice after 24 h stimulation with or without PAR4 AP (150 µM). Data (mean ± SEM; N > 4) were analyzed by 2-way (A, H)
and 1-way (B-G) ANOVA. Statistical significance is shown as * P < 0.05, # P < 0.05 versus unstimulated control within the same genotype or unstimulated control,
and $ P < 0.05 versus poly I:C alone.
replication. In line with this, specific PAR1 stimulation with AP reduced
CVB3 replication in mouse CMs (unpublished data),
3.4. PAR4 stimulation increases natural killer cell like activity of
splenocytes
NK cells are one of the first immune cells infiltrating virus-infected
tissue, killing infected cells and therefore limiting virus replication. A
lack of NK cells was shown to be associated with more a pronounced
viral infection [26]. We analyzed the NK cell-like activity of splenocytes
isolated from WT and ΔPAR4 mice. We found that PAR4 AP increased
NK cell cytotoxicity of WT but not ΔPAR4 splenocytes against the target
cell YAC-1 (Fig. 1H).
3.5. PAR4 deficiency is associated with increased CVB3 myocarditis in mice
To translate our in vitro observations into a human pathologic re-
levant disease, we first used the CVB3 myocarditis model. Four days
after CVB3 infection, hearts of ΔPAR4 mice had reduced protein levels
of IFNβ, and the IFNβ-response genes CXCL10 and CCL5 compared to
hearts of WT mice (Fig. 2A–C). Next, we analyzed the expression of the
proinflammatory mediators CXCL1 and MCP1 in hearts of WT and
ΔPAR4 mice before and 4 days after CVB3 infection. We found that
MCP1 but not CXCL1 expression was higher in CVB3 infected hearts of
ΔPAR4 mice compared with hearts of WT mice (Fig. 2D and E).
Moreover, PAR4-deficiency was associated with higher CVB3 virus
genome levels in hearts 8 days after CVB3 infection (Fig. 2F). In addi-
tion, the more pronounced cardiac inflammation and the higher virus
load was associated with increased cardiac injury, measured by plasma
troponin I levels, in ΔPAR4 compared to WT mice 8 days post infection
(p.i.) (Fig. 2G). Increased acute myocarditis in ΔPAR4 mice resulted in
more severe cardiac hypertrophy measured by an increased heart
weight to tibia ratio in ΔPAR4 mice compared to WT mice 28 days p.i.
(Fig. 2H). Overall, the more severe CVB3 myocarditis in ΔPAR4 mice
resulted in a greater reduction in heart function 28 days p.i. compared
to WT mice (Fig. 2I).
3.6. PAR4 modulates adaptive IgG-dependent immune responses
PAR4 was shown to be expressed in B lymphocytes [27]. Studies
with mice found that increased virus-specific IgGs are detectable from
day 7 onwards post CVB3 infection [28]. To analyze if PAR4 has an
Fig. 2. PAR4 deficiency is associated with increased CVB3 myocarditis in mice. Male wild-type (WT, white bars) and PAR4−/− (ΔPAR4, black bars) mice were
infected with CVB3. Levels of IFNβ (A), CXCL10 (B), CCL5 (C) CXCL1 (D) and MCP1 (E) in the heart before and 4 days after infection were quantified by ELISA. CVB3
genomes in the heart (F) measured by RT-PCR and plasma levels of cardiac troponin I (G) measured by ELISA 8 days after infection. (H) Heart weight to tibia length
as marker for cardiac hypertrophy 28 days after CVB3 infection. (I) Cardiac function shown as fractional shortening were measured by echocardiography before and
28 after CVB3 infection. (J) IgG2a serum levels were analyzed by ELISA before and 8 days after CVB3 infection. Data (mean ± SEM, N > 4) were analyzed by 2-way
ANOVA (A-E, I and J) or by Student’s t-test (F-H) * P < 0.05, # P < 0.05 versus day 0 within the same genotype.
effect on the adaptive immune responses, we analyzed the IgG2a levels
in serum before and 8 days p.i. We found that CVB3 infection increased
the serum levels of IgG2a in both WT and ΔPAR4 mice (Fig. 2J). In-
terestingly, PAR4 deficiency was associated with significant lower le-
vels of IgG2a 8 days p.i. compared to WT mice (Fig. 2J).
3.7. PAR4 deficiency is associated with increased BALF cytokine and
chemokine expression after H1N1 IAV infection of mice
To investigate the effect of PAR4 deficiency in virus infection of the
lung, we infected WT and ΔPAR4 mice with a mouse-adapted H1N1 IAV
and collected BALF. Both genotypes had similar levels of CXCL10,
CXCL1, CCL5 and MCP1 in the BALF prior to H1N1 IAV infection
(Fig. 3). H1N1 IAV infection induced the expression of these in-
flammatory mediators. Interestingly, BALF from ΔPAR4 mice had sig-
nificant higher levels of CXCL10, CXCL1, CCL5 and MCP1 5 days p.i.
with H1N1 IAV compared to WT mice (Fig. 3). However, this differ-
ences between the genotypes were no longer observed at day 7 p.i.
(Fig. 3).
3.8. PAR4 deficiency leads to an early increase in cellular inflammation
into the lung after H1N1 IAV infection of mice
To quantify the amount of cellular inflammation, numbers of total
white blood cells (WBC), neutrophils, lymphocytes and macrophages
were measured before as well as 5 and 7 days after H1N1 IAV infection.
Both genotypes exhibited similar numbers of these cell types in the
BALF prior to H1N1 IAV infection (Fig. 4). As expected, H1N1 IAV
infection led to an infiltration of cells into the lung and airspace of both
genotypes as shown by the increased numbers of immune cells in the
collected BALF 5 and 7 days p.i. (Fig. 4). Interestingly, ΔPAR4 mice
exhibited significant more WBC, neutrophils, lymphocytes and mono-
cytes in BALF 5 days after H1N1 IAV infection (Fig. 4). However, there
were no longer any differences when the cellular content of BALF from
WT and ΔPAR4 was compared at day 7 p.i. (Fig. 4).
3.9. PAR4 deficiency is associated with increased H1N1 IAV genome levels
Virus genome levels in the lung were analyzed 5 days p.i. to in-
vestigate if PAR4 deficiency has an effect of H1N1 IAV titers. As ex-
pected from our observation with CVB3 infection, ΔPAR4 mice had
significantly elevated H1N1 IAV genome levels in the lung compared to
WT mice 5 days p.i. (Fig. 5A).
3.10. PAR4 deficiency has a mild effect on alveolar bleeding after IAV
infection
Recently, we showed that H1N1 IAV infection leads to a mild
bleeding in the lung of mice [22]. Furthermore, the extrinsic pathway
of blood coagulation was required to limit alveolar hemorrhages and
improve survival of H1N1 IAV infected mice [21,22]. Since PAR4 is the
main thrombin receptor on murine platelets, we analyzed markers of
bleeding in BALF collected prior and 5 and 7 days after H1N1 IAV in-
fection of WT and ΔPAR4 mice. Prior to viral infection we found similar
levels of red blood cells (RBC) in BALF of both genotypes (Fig. 5B). As
expected, H1N1 IAV infection led to increased extravasation of RBC
into the airspace of the lung in both WT and ΔPAR4. However, PAR4
deficiency was associated with higher numbers of RBC compared to WT
mice 5 and 7 days after H1N1 IAV infection (Fig. 5B).
3.11. PAR4 deficiency is associated with increased lung pathology after
H1N1 IAV infection of mice
H&E stained lung sections showed that lungs of ΔPAR4 mice ex-
hibited an increase in infiltrating cells in the airspace (bronchial in-
flammation) and increase in overall cellular inflammation within the
lung (interstitial inflammation) compared to WT mice lungs 5 days after
H1N1 IAV infection (Fig. 6).
Fig. 3. PAR4 deficiency is associated with increased alveolar chemokine and cytokine levels after H1N1 IAV infection in mice. Wild-type (WT, white circles) and
PAR4−/− (ΔPAR4, black circles) mice were infected with H1N1 IAV. Protein levels of CXCL10 (A), CXCL1 (B), CCL5 (C) and MCP1 (D) in bronchiolar alveolar lavage
fluid (BALF) prior, 5 and 7 days after infection were analyzed by ELISA. Data (mean ± SEM, N > 8) were analyzed by 2-way ANOVA. * P < 0.05.
3.12. PAR4 deficiency is associated with increased IAV infection-induced
lung injury and mortality of mice
As expected, the increased inflammation resulted in more severe
lung injury in ΔPAR4 mice compared to WT mice as measured by total
protein levels in BALF 5 days after H1N1 IAV infection (Fig. 7A). ΔPAR4
and WT mice exhibited similar changes in body weights after infection
(Fig. 7B). However, PAR4 deficiency was associated with a significantly
increased mortality starting at day 8p.i. compared to infected WT mice
(Fig. 7C). The calculated hazard ratio (HR) for global PAR4 deficient
mice was 2.53 compared to WT mice.
3.13. Platelet inhibition protects mice from H1N1 IAV infection
Since murine platelet PAR4 is needed for maximal platelet activa-
tion, we analyzed the effect of inhibition of thromboxane-mediated
platelet activation by treating mice with ASA or inhibiting the platelet-
dependent ADP signaling by blocking the murine P2Y12 receptor with
clopidogrel. ASA as well as clopidogrel-treated mice showed no dif-
ference in protein levels in BALF either before or 7 days after H1N1 IAV
infection compared to vehicle treated control mice (Fig. 8A). However,
clopidogrel and ASA treatment resulted in significant better recovery of
body weights starting 8 and 9 days after IAV infection, respectively
(Fig. 8B). Interestingly, only ASA treatment protected mice from H1N1
Fig. 4. PAR4 deficiency is associated with increased immune cell infiltration into the airways of the lung in mice. Wild-type (WT, white circles) and PAR4−/−
(ΔPAR4, black circles) mice were infected with H1N1 IAV. Numbers of white blood cells (WBC, A), neutrophils (B), lymphocytes (C) and monocytes (D) in BALF
prior, 5 and 7 days after infection were quantified by HemoVet. Data (mean ± SEM, N > 5) were analyzed by 2-way ANOVA. * P < 0.05.
Fig. 5. PAR4 deficiency is associated with increased H1N1 IAV load and mild alveolar bleeding. Wild-type (WT, white circles) and PAR4−/− (ΔPAR4, black circles)
mice were infected with H1N1 IAV. (A.) H1N1 IAV genome levels were analyzed in lungs 5 days after infection by RT-PCR. (B.) Numbers of red blood cells (RBC)
were analyzed in BALF prior, 5 and 7 days after H1N1 IAV infection. Data (mean ± SEM, N > 8) were analyzed by Mann-Whitney U test (A) and by 2-way ANOVA
(B). * P < 0.05.
IAV-induced death (Fig. 8C). The calculated HR for ASA compared to
vehicle treatment is 0.137 whereas for clopidogrel compared to vehicle
treatment is only 0.630.
4. Discussion
In this study, we used global PAR4 deficient mice to investigate the
role of PAR4 in two human disease relevant virus infection models
CVB3 myocarditis and H1N1 IAV infection. We observed that PAR4
protects the heart and lung against CVB3 and H1N1 IAV infection, re-
spectively. As previously shown for PAR1, we observed that PAR4 en-
hanced TLR3:IRF3-dependent IFN responses by increasing IFNβ and
CXCL10 expression in vivo and in vitro. We think that PAR1 and PAR4
use a common pathway in positively increasing TLR3-dependent anti-
viral signaling possibly via enhancing p38 activation [8]. Interestingly,
we found that while PAR4 enhances the TLR3:IRF3 pathway it dampens
the TLR3:NFκB pathway leading to reduced expression of proin-
flammatory mediators, such as TNFα, MCP1 and CXCL1. Our findings
contribute to studies by us and others that thrombin-activatable PARs
enhance antiviral TLR3 responses [8,11,12,29].
4.1. PAR4 in CVB3 myocarditis
We showed that thrombin as well as PAR1 contributes to an innate
immune responses to CVB3 or the TLR3 agonist poly I:C [8,11]. This
effect was due to PAR1-dependent TLR3 pathway enhancement on
cardiac fibroblasts, cardiac myocytes, macrophages and splenocytes
[8,11]. Interestingly, in CVB3 infection, platelets were identified as a
major factor in limiting CVB3 myocarditis by reducing systemic viremia
and enhancing immune cell function [30]. However, the study did not
show that platelet activation was needed for the protection [30]. Im-
portant for our findings, PAR4 is not only expressed on murine platelets
but it is also expressed by other cells, such as on CMs and immune cells
[3,17,27,31]. Whether PAR4 is expressed by all kinds of fibroblast
subtypes is still in question [3,32,33]. For instance, we found MEFs but
not cardiac fibroblasts to express detectable PAR4 mRNA (data not
shown) and are responsive to PAR4 stimulation. In this study, we
showed that PAR4 activation enhances TLR3-dependent CXCL10 ex-
pression in BMMs and MEFs. CXCL10 mediates antiviral properties by
recruiting NK cells to infected tissues [26]. Furthermore, we observed
that PAR4 activation reduced TLR3-dependent NFκB responses, in at
least WT MEFs and CMs, leading to reduced expression of MCP1 and
TNFα when TLR3 and PAR4 were co-stimulated. This PAR-dependent
reduction in NFκB-dependent TLR3 responses was recently proposed by
us for PAR1 [1]. Recruitment of macrophages into the heart was shown
to be MCP1-dependent [34]. Furthermore, reduced cardiac MCP1 levels
as well as cardiac macrophages numbers were associated with im-
proved CVB3 myocarditis [35]. Our data point to a PAR4-dependent
effect in reducing myocardial inflammation possibly by inhibiting the
MCP1-macrophage axis.
We found increased CVB3 genomes in the heart of ΔPAR4 mice
compared to WT mice after infection. The differences in viral genome
levels appears to be due to the impaired anti-viral TLR3 immune re-
sponses in ΔPAR4 mice rather than to a PAR4-dependent effect on viral
replication. We did not see any changes in viral replication when CMs
were stimulated with PAR4 AP while thrombin reduced CVB3 genomes
levels. This suggest that PAR1 rather than PAR4 reduced CVB3 re-
plication in CMs.
4.2. Effect of PAR4 stimulation on NK cell-like activity of splenocytes
NK are important in limiting viral spreading, including CVB3, by
killing virus infected cells [26]. In addition, thrombin activation was
shown to increase NK cell-like activity in human peripheral blood
lymphocytes [36]. In the past, we showed that PAR1 activation en-
hances NK cell-like cytotoxicity of mouse splenocytes [8]. In addition to
PAR1, NK cells express also PAR4 [37]. We found that NK cell-like
activity of splenocytes was increased in a PAR4-dependent way, sug-
gesting that PAR4 directly influences NK cell function possibly via in-
crease IL-2 release as shown for thrombin stimulation of human NK
cells [36].
4.3. PAR4 in adaptive immune responses in CVB3 myocarditis
To analyze the possible effect of PAR4 on the adaptive immune
system, we measured IgG responses after CVB3 infection in WT com-
pared to ΔPAR4 mice. IgG2a titers increases after viral infections [38].
IgG in particular IgG2a were linked to increased viral elimination of
CVB3 and other viruses [28,39,40]. Moreover, IgG2a expression was
dependent to IFNγ-dependent signaling after virus infection [39,40].
IgG2a antibodies were shown to be more effective in activating com-
plement, stimulating macrophages through the IgG Fc receptor and
enhancing antibody-dependent cellular cytotoxicity [41,42]. While
ΔPAR4 mice had a more pronounced CVB3 myocarditis 8 days after
Fig. 6. PAR4 deficiency is associated with increased bronchial and interstitial immune cell infiltration after H1N1 in mice. Representative H&E stained formalin and
paraffin-embedded section lungs from wild-type (WT) and PAR4−/− (ΔPAR4) mice 5 days after H1N1 IAV infection. Bronchial (arrow) and interstitial (arrow head)
immune cell infiltration within the lung are indicated. Size bar= 500 µm.
infection their serum IgG2a levels were significant lower compared to
WT mice. This suggest that PAR4 plays a role in adaptive IgG2a im-
mune responses at least to CVB3. Interestingly, it was shown that pla-
telets enhance the total IgG response after CVB3 infection [30]. Whe-
ther the platelet dependent effect on IgG levels after CV3 infection and
our observation was due to platelet PAR4 or independent of each other
needs further investigation.
4.4. PAR4 in H1N1 IAV infection
The seasonal flu is a reoccurring public health threat causing serious
morbidity and mortality in the young and elderly population. Our study
is in contrast to the findings by another study [18]. Here, we showed
that a lack of PAR4 leads to a more pronounced H1N1 influenza A
Fig. 7. PAR4 deficiency is associated with increased lung injury and mortality
after IAV infection. Wild-type (WT, white circles) and PAR4−/− (ΔPAR4, black
circles) mice were infected with H1N1 IAV. (A) Lung injury was quantified by
total protein concentration in BALF prior, 5 and 7 days after infection. Changes
in body weights (B) and calculated survival (C) over 14 days after infection
(N=17 for WT and N=23 for ΔPAR4). Body weights before infection were set
to 100%. Data (mean ± SEM) and calculated survival were analyzed by 2‐way
ANOVA (A and B) or log‐rank test (C). * P < 0.05.
Fig. 8. Pharmacologic platelet inhibition mediates protection against H1N1
IAV infection in mice. Wild-type mice were treated with vehicle (control, white
circles), acetylsalicylic acid (ASA, 0.4mg/mL, black triangles) or clopidogrel
(0.15 mg/mL, black squares) in drinking water 3 days prior and after H1N1 IAV
infection. A.) Protein levels in BALF of mice treated with vehicle, ASA or clo-
pidogrel before and 7 days after H1N1 IAV infection. Changes in body weights
(B) and calculated survival (C) over 14 days after H1N1 IAV infection (N=17
for vehicle, N= 15 for ASA and N=8 for clopidogrel). Body weights before
infection were set to 100%. Data (mean ± SEM) and calculated survival were
analyzed by 2‐way ANOVA (A, B) or log‐rank test (C). * P < 0.05, # P < 0.05
IAV+ASA versus IAV (vehicle) alone, $ P < 0.05 IAV+ clopidogrel versus
IAV (vehicle) alone.
inhibitors or activators [18,52]. However, as with all inhibitors there
are concerns with specificity of these agents. Most of the studies lack
control experiments to show that the compounds act via a PAR4-de-
pendent mechanism. In addition, some of the PAR4 inhibitors were
shown to act as biased agonists in vitro [57]. Importantly, various PAR
activators and inhibitors showed PAR-independent actions [1,57–61].
For instance, the pepducin P4pal-10 was thought to block only PAR4
signaling [62]. However, it was shown that P4pal-10 inhibits other
Gαq-coupled receptors, including PAR1, M3 muscarinic acetylcholine
receptor, H1 histamine receptor and thromboxane A2 receptor [60,61].
The opposing results by Lê et al. [18] that PAR4 inhibition is protective
in H1N1 IAV infection could therefore be explained by an off-target
effect of P4pal-10 blocking the thromboxane A2 receptor [61] mi-
micking an ASA treatment leading to improved survival after H1N1 IAV
infection.
In conclusion, our data suggest that platelet-independent PAR4
mediates protective signaling possibly on resident and immune cells to
limit certain RNA virus infections. We do not think our observation was
due to compensation by other PARs since a recent study showed that
PAR4 deficiency does not influence the expression of other PARs [17].
Platelet PAR4 was identified as drug-able target to reduce thrombotic
events. However, our data indicate that PAR4 is needed for effective
anti-viral responses. Our findings point to a potential risk that the use of
a PAR4 antagonists could lead to an increased incident and severity of
certain virus infection in patients. This risk should be investigated in
future studies.
Study limitations
We cannot finally exclude the potential contribution of PAR4 on
platelets in H1N1 IAV or CVB3 infection. The use of a conditional PAR4
knock-out mouse will help to analyze the cell-specific contribution of
PAR4 in various diseases models including H1N1 IAV infection and
CVB3 myocarditis. Importantly, additional studies with PAR4 antago-
nists in WT and ΔPAR4 mice are needed.
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